12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Linaclotide acetate: Phase IIb completed

In a double-blind, placebo-controlled, dose-escalating, U.S. and Canadian Phase IIb trial in 419 patients with IBS-C, all 4 doses of linaclotide met the primary endpoint of change in CSBM frequency vs. placebo. Patients received placebo, 75, 150, 300 or 600 µg linaclotide...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >